Abstract Pharmacological treatment of Chagas disease is based on benznidazole, which displays poor efficacy when administered during the chronic phase of infection. Therefore, the development of new therapeutic options is needed. This study reports on the structural design and synthesis of a new class of anti-Trypanosoma cruzi thiazolidinones (4 a–p).(2-[2- Phenoxy-1-(4-bromophenyl) ethylidene) hydrazono]-5-ethylthiazolidin-4-one (4 h) and (2-[ ...
